EDITION:
- EU
- NA
A groundbreaking achievement is flying under the radar. Epidiolex, the first FDA approved cannabis-derived drug developed by GW Pharmaceuticals, is on track to surpass $1 billion in annual revenue—a feat that puts it in the league of blockbuster drugs like Humira and Lipitor.
Cannabis capital markets have faced significant challenges over the past few years. As investors who have been actively involved in the industry since 2019, we have had the privilege of experiencing every market cycle – from euphoric highs to sobering lows.
As Canada’s cannabis industry stands at a pivotal crossroads, the impending departure of Prime Minister Justin Trudeau marks the end of an
Ahead of the release of Prohibition Partners upcoming Global Cannabis Report: 5th Edition, we sat down with Sebastian Zeller, Managing
The North American cannabis industry in 2024 experienced a pivotal year of progress and challenges, setting the stage for a
Written by Ben Stevens and Sarah Sinclair. You can read Part 1 here. Growing demand for medical cannabis across Europe
Written by Ben Stevens and Sarah Sinclair. 2024 has been a dramatic year for the global cannabis industry, seeing
Creating a culture that focuses on the behaviours required to achieve the results desired, has been the root cause of Releaf’s success in the UK’s medical cannabis sector – a sector that has stagnated since medical cannabis became legal in 2018.
Business of Cannabis recently sat down with Releaf’s Chief Operating Officer, Graham Woodward, a trained psychiatric nurse and former clinical director and CQC Specialist Advisor, to discuss the impact of the lack of access to training how clinics such as Releaf are working to change it.Â
Written by Deb Tharp, activist and political consultant. We were on the cusp of full federal recognition of medical cannabis.
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
